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Introduction
Rheumatoid arthritis (RA) is a promising new target for
gene therapy (reviewed in [1]). One approach to the
genetic therapy of RA requires the transfer of anti-arthritis
genes to the synovial linings of joints [2]. The first human
trial of arthritis gene therapy approved by the Recombinant
DNA Advisory Committee (RAC) of the National Institutes
of Health and by the US Food and Drug Administration
(FDA) involves the ex vivo, retroviral delivery to joints of a
cDNA encoding the human interleukin-1 receptor antago-
nist (IL-1Ra) [3]. The procedure has been shown to be safe
and effective in several animal models of RA [4–7].
When rabbit type B synoviocytes are transduced with the
amphotropic retrovirus MFG-IRAP under standard, static
conditions, they routinely secrete approximately 100 ng
human IL-1Ra/106 cells per 48 h into their culture medium
[7]. For the purposes of the clinical trial, transduced
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This report concerns a clinical trial for rheumatoid arthritis (RA), approved by the US National Institutes
of Health and the Food and Drug Administration. An amphotropic retrovirus (MFG-IRAP) was used ex
vivo to transfer a cDNA encoding human interleukin-1 receptor antagonist (IL-1Ra) to synovium. The
protocol required the transduced cells to secrete at least 30 ng IL-1Ra/106 cells per 48 h before
reimplantation. Here we have evaluated various protocols for their efficiency in transducing cultures of
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(approximately 108 infectious particles/ml). Transduction efficiency was increased further by exposing
the cells to virus under flow-through conditions. The use of dioctadecylamidoglycylspermine (DOGS)
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human synoviocytes were required to secrete at least
30 ng IL-1Ra/106 cells per 48 h [3]. We investigated
several transduction strategies in order to identify condi-
tions that result in the highest transduction efficiency for
use in this clinical trial. This communication describes
attempts to improve the transduction efficiency of human
rheumatoid synoviocytes by MFG-IRAP.
Materials and Methods
Cell culture
Synovial tissue was recovered from joints of five patients
undergoing surgery for the management of their RA.
Cells were isolated by sequential digestion of synovium
with trypsin and collagenase, counted with a hemocy-
tometer, cultured in Ham’s F-12 medium supplemented
with 10% (v/v) fetal bovine serum and antibiotics, and
seeded into 25 cm2 plastic culture flasks with 4 ml
medium at a density of 5 × 105 cells per flask (passage
0) [8]. Viabilty of >95% was confirmed by staining with
trypan blue. Among cells of passage 0, type A and type
B synovial fibroblasts and macrophages were the pre-
dominant adherent cells and lymphocytes were the pre-
dominant nonadherent cells. The latter were removed by
medium changes every 3 days. Confluent cells were
detached by trypsinizing, washed, and reseeded into 6-
well culture plates at a density of 0.5–1.0 × 105 cells per
well (first-passage cells) or into 25 cm2 flasks. When the
flasks reached confluence, they were trypsinized and
seeded into six-well plates at a density of 0.5–1.0 × 105
cells per well (second-passage cells). Since type-A syn-
oviocytes and macrophages are lost during trypsiniza-
tion, passage 1 and passage 2 cells consist of type B
synovial fibroblasts.
Vectors
The construction of a y-CRIP [9] producer line for MFG-
IRAP has been previously described [7]. The Human
Gene Therapy Applications Laboratory of the University of
Pittsburgh Medical Center produced clinical grade virus.
The titer of this retroviral preparation was found to be
5×1 0 5 infectious particles/ml. This preparation is referred
to as ‘standard titer’ retrovirus. High titer MFG-IRAP was
produced by concentration using tangential flow filtration
and size exclusion chromatography [10].
MFG-LacZ was also generated using the y-CRIP pro-
ducer line. This vector contains the b-galactosidase gene,
and was used as a marker of gene expression.
Transduction of synoviocytes
Transductions were carried out in six-well plates on
passage 1 or passage 2 cells as noted below. On day 1,
cells were plated at a density of 0.5–1.0 × 105 cells per
well. When the cells were 50–60% confluent, the culture
medium was removed and replaced with 3 ml of super-
natant containing standard-titer MFG-IRAP, standard titer
MFG-LacZ, high titer MFG-IRAP, or medium alone. All
transductions were carried out in the presence of Poly-
brene (8 mg/ml) or dioctadecylamidoglycylspermine
(DOGS) (5 mg/ml), as indicated.
For static transductions, viral supernatants were added to
the cultures, which then were returned to the incubator for
2 h (one patient), 6 h (one patient) or 12 h (three patients),
after which time the viral suspensions were replaced with
3 ml of fresh culture medium. For double static transduc-
tion, the media were removed 24 h from the time of the
initial transduction and the process was repeated. In
another series of experiments, the retroviral supernatants
were allowed to remain on the cells for 24, 48, 72, or
96 h, with a change of retroviral supernatant every 24 h. At
the end of the transduction period, all cells were washed
with Gey’s balanced salt solution and then 4 ml of culture
medium was added to each well.
For transduction during centrifugation, the plates were
centrifuged at 2000 g at 32°C during the 2 h transduction
period. Centrifugation resulted in the development of a
crescent-shaped ‘dry’ area in the center of each well.
Because the cells in these areas were deprived of liquid
during the transduction period, they did not survive. The
dry areas were estimated to comprise approximately 10%
of the area of the well.
For flow-through transduction, the method of [11] was
followed. Briefly, synoviocytes were cultured on colla-
gen-coated inserts (Transwell-COLTM from Costar),
which were then placed into six-well plates. Retroviral
supernatants (1 ml) were placed in the upper well and
allowed to flow through the monolayer under gravity.
After 8 h, the cells were washed and culture media were
added to the wells.
Gene expression
After transduction, 4 ml of supplemented Ham’s F-12
medium was added to each well, plates were returned to
the incubator, and cells were allowed to reach conflu-
ence. Once the cells were confluent, the media were
removed and the cells were washed with 4 ml Gey’s bal-
anced salt solution, which was then replaced with 4 ml
culture medium. After 48 h, conditioned media were col-
lected and stored at –20°C until they were assayed for
IL-Ra expression. Cells were trypsinized and counted
using a hemocytometer. Concentrations of IL-1Ra in the
conditioned media were determined by ELISA (R&D
Systems, Minneapolis, MN). Expression of LacZ was
ascertained by histochemical staining with 5-bromo-4-
chloro-3-indoyl-b-D-galactoside (X-gal) using standard
techniques [7].
Data were analyzed with the statistical software Statview
4.5; unpaired t-tests were used to compare groups.c
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Results
Four different methods of retroviral transduction of
rheumatoid synovium were compared: A) one static trans-
duction at passage 1; B) one static transduction at
passage 2; C) transduction at passage 1 during centrifu-
gation; D) two static transductions made 24 h apart during
passage 1 (Fig. 1).
Cells transduced once at passage 1 by static infection
with standard-titer MFG-IRAP secreted 14.2 ± 2.8 ng
IL-1Ra/106 cells per 48 h. None of the cultures secreted
the ³30 ng IL-1Ra/106 cells per 48 h required by the clini-
cal protocol. Similar results were obtained with second
passage cells. Static transduction twice within a passage
resulted in an average secretion of 33.8 ± 8.7 ng
IL-1Ra/106 cells per 48 h, but only two of the five cultures
secreted more than 30 ng/106 cells per 48 h. First
passage cells transduced once while being centrifuged
secreted 110 ± 8.0 ng IL-1Ra/106 cells per 48 h
(P<0.0001 vs one or two static transductions) and all
five cultures exceeded the cutoff threshold of
30 ng/106cells per 48 h. Routine static transductions with
MFG-LacZ vector, carried out in parallel with these experi-
ments, resulted in approximately 30% LacZ+ cells,
whereas transductions carried out during centrifugation
resulted in nearly 100% transduction.
Lowering the temperature from 37 to 32°C or increasing
the volume of the retroviral supernatant from 1 to 3 ml per
well produced small (25% or less; statistically insignifi-
cant) improvements in transgene expression (data not
shown). Increasing the time of transduction beyond 24 h
raised the transduction efficiency considerably (Fig. 2).
With transduction periods of 48 and 72 h, all cultures pro-
duced at least 30 ng IL-1Ra/106 cells per 48 h.
In another series of experiments, high titer MFG-IRAP, flow-
through transduction [11], and DOGS [12] instead of Poly-
brene were evaluated for their effects on transduction
efficiency and gene expression (Table 1). Qualitatively
equivalent results were obtained with two different patients
in triplicate experiments. Transduction was significantly
more efficient with high titer than with low titer virus, regard-
less of the polycation used (P<0.05) or the transduction
method (static or flow-through). The flow-through transduc-
tion method was significantly better (P<0.05) than static
transduction when Polybrene was used. In the presence of
DOGS, flow-through transduction was significantly better
than static transduction if low titer virus was used
(P<0.05). Overall, DOGS did not consistently provide sig-
nificantly better transduction efficiency than Polybrene.
Discussion
These data support a growing body of evidence that cen-
trifuging enhances the efficiency of retroviral transduction
[13]. Similar experiments using MFG-LacZ confirmed that
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Figure 1
IL-1Ra production by human synoviocytes after transduction by MFG-
IRAP under various conditions. Monolayer cultures of synoviocytes
from five different patients with RA were transduced with standard-titer
MFG-IRAP under the following conditions: A) first passage cells; static
conditions; single transduction; B) second passage cells; static
conditions; single transduction; C) first passage cells; with
centrifuging; single transduction; D) first passage cells; static
conditions; double transduction. Each point represents the average of
two determinations for each patient under the indicated conditions. To
the left of each column are the overall means for each method ± SD.
The dashed line indicates the minimum level of 30 ng IL-1Ra/106 cells
per 48 h required by the clinical protocol. IL-1Ra production after
transduction with centrifuging (column C) exceeds all other methods,
with P < 0.0001.
Figure 2
IL-1Ra production by human synoviocytes after static transduction for
extended periods. Monolayer cultures of synoviocytes from five different
patients with RA were transduced statically in duplicate with standard
titer MFG-IRAP for the indicated lengths of time. Supernatants were
changed every 24 h, until transductions were completed for all cultures.
The cells were then washed, given complete media, and incubated for a
further 48 h. At this time, media were harvested and IL-1Ra content was
determined. Values are means ± SD. IL-1Ra production increased
significantly (P < 0.05) when the time of transduction was increased
from 24 to 48 h and from 48 to 72 h.centrifuging increased the proportion of transduced cells,
suggesting that the main effect is on transduction effi-
ciency. The disadvantage of centrifuging is loss of cells
due to the formation of lunate dry areas. Increasing the
volume of supernatant minimizes these dry areas, but
increases the consumption of supernatant.
Length of exposure to retroviral supernatant also affected
transduction. The MFG retroviral vector used in this study
is based on the Moloney murine leukemia virus, which pro-
vides all the elements necessary for infection of target
cells. The half-life of Moloney-based retroviruses at 37°C
is 6–9 h [14], so they would survive long enough to trans-
duce cells as they entered mitosis during prolonged incu-
bations. The plateau in efficiency between 72 and 96 h of
transduction probably reflects the fact that the cells
became confluent during that time.
In general, our data using flow-through transduction
support those of Chuck and Palsson [11]. The disadvan-
tage of the flow-through method was the need for regular
attention to ensure that wells had not run dry and to
recycle the viral supernatant. However, the method was
economical, because it was possible to cycle 1 ml of
supernatant over the cells. Flow-through improved IL-1Ra
expression using the lower titer virus, but the degree of
enhancement differed between the two patients; in one,
there was an approximately 3- to 8-fold increase, depend-
ing on whether Polybrene or DOGS was used (Table 1).
In the other patient, increases of approximately 20- and
30-fold were obtained. The improving effects of the flow-
through method were less dramatic with high titer virus,
where transduction was already higher under static condi-
tions, but increases of up to 3-fold were obtained.
Increasing the titer of the retrovirus improved transduction
efficiencies 25- to 30-fold when Polybrene was used and
approximately 40-fold when DOGS was used. Although
the results were not as dramatic as those reported by
Themis and colleagues [12], the use of DOGS instead of
Polybrene gave a small to moderate improvement in
IL-1Ra production. Overall, the highest levels of transgene
expression were obtained using high titer retrovirus in
combination with flow-through transduction conditions.
These values far exceeded those obtained by centrifuging
with standard titer virus. The effects of centrifuging with
high titer virus were not evaluated.
Conclusions
Collectively, these data suggest that, of the parameters
evaluated here, the single biggest improvement in retrovi-
ral transduction of human synoviocytes is obtained with
high titer retrovirus. Further increases in transgene expres-
sion were achieved by using high titer retrovirus with flow-
through transduction or centrifuging. When these factors
were combined, IL-1Ra production was increased 50- to
100-fold relative to static transductions performed with
standard titer virus. Improvements of this magnitude will
be particularly important when performing gene therapy
with transgenes such as IL-1Ra, which need to be pro-
duced in large molar excess over the molecules whose
activities they antagonize [15].
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